Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 18


The challenges and the promise of molecular targeted therapy in malignant gliomas.

Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D, Chen J.

Neoplasia. 2015 Mar;17(3):239-55. doi: 10.1016/j.neo.2015.02.002. Review.


Pax3 expression enhances PDGF-B-induced brainstem gliomagenesis and characterizes a subset of brainstem glioma.

Misuraca KL, Barton KL, Chung A, Diaz AK, Conway SJ, Corcoran DL, Baker SJ, Becher OJ.

Acta Neuropathol Commun. 2014 Oct 21;2:134. doi: 10.1186/s40478-014-0134-6.


Contemporary murine models in preclinical astrocytoma drug development.

McNeill RS, Vitucci M, Wu J, Miller CR.

Neuro Oncol. 2015 Jan;17(1):12-28. doi: 10.1093/neuonc/nou288. Epub 2014 Sep 21. Review.


Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner.

Karabeber H, Huang R, Iacono P, Samii JM, Pitter K, Holland EC, Kircher MF.

ACS Nano. 2014 Oct 28;8(10):9755-66. doi: 10.1021/nn503948b. Epub 2014 Aug 22.


Glioblastoma multiforme: State of the art and future therapeutics.

Wilson TA, Karajannis MA, Harter DH.

Surg Neurol Int. 2014 May 8;5:64. doi: 10.4103/2152-7806.132138. eCollection 2014. Review.


In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift.

Halliday J, Helmy K, Pattwell SS, Pitter KL, LaPlant Q, Ozawa T, Holland EC.

Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5248-53. doi: 10.1073/pnas.1321014111. Epub 2014 Mar 24.


Spatial and cellular characterization of mTORC1 activation after spinal cord injury reveals biphasic increase mainly attributed to microglia/macrophages.

Kjell J, Codeluppi S, Josephson A, Abrams MB.

Brain Pathol. 2014 Nov;24(6):557-67. doi: 10.1111/bpa.12135. Epub 2014 Mar 28.


Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules.

Leder K, Pitter K, Laplant Q, Hambardzumyan D, Ross BD, Chan TA, Holland EC, Michor F.

Cell. 2014 Jan 30;156(3):603-16. doi: 10.1016/j.cell.2013.12.029.


The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression.

Sonabend AM, Bansal M, Guarnieri P, Lei L, Amendolara B, Soderquist C, Leung R, Yun J, Kennedy B, Sisti J, Bruce S, Bruce R, Shakya R, Ludwig T, Rosenfeld S, Sims PA, Bruce JN, Califano A, Canoll P.

Cancer Res. 2014 Mar 1;74(5):1440-51. doi: 10.1158/0008-5472.CAN-13-2150. Epub 2014 Jan 3.


One mouse, one patient paradigm: New avatars of personalized cancer therapy.

Malaney P, Nicosia SV, Davé V.

Cancer Lett. 2014 Mar 1;344(1):1-12. doi: 10.1016/j.canlet.2013.10.010. Epub 2013 Oct 22. Review.


Diffusion-Weighted MRI as a Biomarker of Tumor Radiation Treatment Response Heterogeneity: A Comparative Study of Whole-Volume Histogram Analysis versus Voxel-Based Functional Diffusion Map Analysis.

Lemasson B, Galbán CJ, Boes JL, Li Y, Zhu Y, Heist KA, Johnson TD, Chenevert TL, Galbán S, Rehemtulla A, Ross BD.

Transl Oncol. 2013 Oct 1;6(5):554-61. eCollection 2013.


PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.

Pal I, Mandal M.

Acta Pharmacol Sin. 2012 Dec;33(12):1441-58. doi: 10.1038/aps.2012.72. Epub 2012 Sep 17. Review.


Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ.

Cancer. 2012 Dec 15;118(24):6055-62. doi: 10.1002/cncr.27668. Epub 2012 Jun 6.


DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.

Galbán S, Lemasson B, Williams TM, Li F, Heist KA, Johnson TD, Leopold JS, Chenevert TL, Lawrence TS, Rehemtulla A, Mikkelsen T, Holland EC, Galbán CJ, Ross BD.

PLoS One. 2012;7(4):e35857. doi: 10.1371/journal.pone.0035857. Epub 2012 Apr 20.


Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.

Carico C, Nuño M, Mukherjee D, Elramsisy A, Dantis J, Hu J, Rudnick J, Yu JS, Black KL, Bannykh SI, Patil CG.

PLoS One. 2012;7(3):e33684. doi: 10.1371/journal.pone.0033684. Epub 2012 Mar 29.


Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine.

Sun W, Modak S.

Onco Targets Ther. 2012;5:21-9. doi: 10.2147/OTT.S14578. Epub 2012 Mar 2.


Review: insights gained from modelling high-grade glioma in the mouse.

Rankin SL, Zhu G, Baker SJ.

Neuropathol Appl Neurobiol. 2012 Jun;38(3):254-70. doi: 10.1111/j.1365-2990.2011.01231.x. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk